Environmental

NKTX appears to have limited direct environmental exposure as a biotechnology company, so peer-relative environmental risk is generally lower than for manufacturing-intensive life sciences peers.

The provided metrics show no meaningful R&D intensity signal, which limits evidence of environmental resource burden but also prevents a stronger sustainability advantage versus peers.

With no disclosed emissions, energy, or waste data in the prompt, environmental positioning remains difficult to verify and therefore sits near the middle of the peer set.

Any environmental upside is mainly structural from a lab-based business model, while the absence of transparent operational disclosures keeps the score below stronger peer leaders.

Social

NKTX’s biotechnology profile typically implies high dependence on scientific talent, which can support workforce quality but also creates peer-level competition for specialized labor.

The zero stock-based compensation-to-revenue metric in the prompt suggests limited dilution pressure, which may modestly improve employee alignment versus more equity-heavy peers.

No patient-safety, product-access, or clinical-trial conduct disclosures were provided, so social risk assessment remains constrained and cannot justify a stronger relative score.

Overall social positioning is mixed because the company likely benefits from a knowledge-intensive model, yet the lack of disclosed workforce and trial-practice metrics limits peer differentiation.

Governance

The debt-to-equity ratio of 0.30 and negative net debt-to-EBITDA indicate a relatively conservative balance sheet, which can reduce governance pressure versus more levered peers.

Zero stock-based compensation-to-revenue in the prompt suggests restrained compensation dilution, supporting cleaner capital discipline than many development-stage biotech comparables.

However, no board independence, audit, or shareholder-rights data were provided, so governance strength cannot be confirmed beyond the limited capital-structure signals.

On the available evidence, NKTX looks somewhat better governed than highly levered or heavily dilutive peers, but not clearly top-tier without fuller disclosure.

Overall Score

NKTX screens as a mid-pack ESG name versus biotech peers, with its strongest relative feature being conservative capital structure and its main limitation being sparse disclosure.

Score Driver: Conservative Leverage And Limited Dilution Support A Modest Governance Edge, But Incomplete ESG Disclosure Caps The Overall Relative Score.